A Phase 2 interventional study of Humalog and Humulin-R in Diabetes Mellitus, Type 2, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-08-18.
Sponsored by Halozyme Therapeutics · Phase 2 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 2.
Among the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2, this one is the 33rd largest by enrollment, is one of 2 that started in 2009, is one of 2 in phase 2, and was the 12th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 127 across the 36 interventional studies. Of the 34 that completed or were terminated, 28 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 10 most frequent:
Halozyme Therapeutics is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Halozyme Therapeutics has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center, Phase 2, randomized, double-blind, 3-way crossover meal study in participants with Type 2 Diabetes Mellitus (T2DM) to determine the optimum dose and compare the pharmacokinetics (PK) and postprandial glycemic response of Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), and Humulin-R + rHuPH20 administered subcutaneously.
This study design was chosen to assess the differences between pharmacokinetic (PK) and pharmacodynamic (PD) parameters, including postprandial glycemic response, of Humalog + recombinant human hyaluronidase PH20 (rHuPH20), Humalog alone, and Humulin-R + rHuPH20 at optimal doses following a liquid meal.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout period), followed by a SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3 to 14 day washout period.
Drug: Humalog · Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
Drug: Humalog · Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase PH20(rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
Drug: Humalog · Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog following a 3- to 14-day washout period.
Drug: Humalog · Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
Drug: Humalog · Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog alone following a 3- to 14-day washout period.
Drug: Humalog · Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
Postprandial Glucose (PPG) Excursion Following a Liquid Meal
Postprandial glucose (PPG) values in participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal are reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug. Least square mean difference was calculated and tested using repeated measures analysis of variance with fixed effect for treatment.
Time frame: Predose up to 480 minutes after study drug injection
Maximum Serum Insulin Concentration (Cmax)
Maximum serum insulin concentration (Cmax) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.
Time frame: Predose up to 480 minutes after study drug injection
Time To Maximum Serum Insulin Concentration (Tmax)
Time to maximum serum insulin concentration (Tmax) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.
Time frame: Predose up to 480 minutes after study drug injection
Time to Early 50% Maximum Serum Insulin Concentration (Early[t50%])
Time to early 50% maximum serum insulin concentration (early\[t50%\]) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, and 120 minutes after injection of each study drug.
Time frame: Predose up to 120 minutes after study drug injection
Time to Late 50% Maximum Serum Insulin Concentration (Late[t50%])
Time to late 50% maximum serum insulin concentration (late\[t50%\]) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.
Time frame: Predose up to 480 minutes after study drug injection
Mean Residence Time From Time 0 to the End of Blood Sampling (MRT[Last])
Mean residence time from time 0 to the end of blood sampling (MRT\[last\]) for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.
Time frame: Predose up to 480 minutes after study drug injection
Area Under the Concentration Time-Curve for Serum Insulin From Time 0 to the End of Blood Sampling (AUC[Last])
Area under the concentration time-curve for serum insulin from time 0 to the end of blood sampling (AUC\[last\]) for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 during a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug. Least squares mean difference was calculated and tested using repeated measures analysis of variance with fixed effect for treatment.
Time frame: Predose up to 480 minutes after study drug injection
Area Under the Time-Concentration Curve for Blood Glucose (AUC[BG])
Area under the time-concentration curve for blood glucose (AUC\[BG\]) for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), and Humulin-R + rHuPH20 following a liquid meal is reported. AUC(BG) values are reported for participants whose blood glucose (BG) was elevated higher than 160 milligrams per deciliter (mg/dL) or 140 mg/dL, or lower than 70 mg/dL within 4 hours of consuming a liquid meal. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug. Least squares mean difference was calculated and tested using repeated measures analysis of variance with fixed effect for treatment.
Time frame: Predose up to 480 minutes after study drug injection
Minimum Postprandial Glucose (PPG)
Minimum postprandial glucose (PPG) in participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.
Time frame: Predose up to 480 minutes after study drug injection
Percentage of Participants Without Hypoglycemia
Percentage of participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 who did not experience hypoglycemia following a liquid meal is reported. Hypoglycemia was defined as any blood glucose values lower than 70 milligrams per deciliter (mg/dL) or symptoms of hypoglycemia responding to treatment with glucose. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.
Time frame: Predose up to 480 minutes after study drug injection
Time to Percentage of Insulin Exposure (as Measured by Area Under the Curve [AUC])
Time to percentage of exposure to insulin, as measured by area under the curve (AUC), following a liquid meal for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.
Time frame: Predose up to 480 minutes following after injection of study drug
| Milestone | Humalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20 | Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20 | Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20 | Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then Humalog | Humulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20 | Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 3 | 4 |
| Received at least 1 dose of study drug | 4 | 4 | 4 | 4 | 3 | 4 |
| Completed | 3 | 4 | 4 | 4 | 3 | 4 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Humalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20 | Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20 | Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20 | Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then Humalog | Humulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20 | Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog |
|---|---|---|---|---|---|---|
| Started | 3 | 4 | 4 | 4 | 3 | 4 |
| Completed | 3 | 4 | 4 | 4 | 3 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Humalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20 | Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20 | Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20 | Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then Humalog | Humulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20 | Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog |
|---|---|---|---|---|---|---|
| Started | 3 | 4 | 4 | 4 | 3 | 4 |
| Completed | 3 | 4 | 4 | 3 | 3 | 4 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Weight loss > 3 kilograms (kg) | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Humalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20 | Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20 | Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20 | Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then Humalog | Humulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20 | Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog |
|---|---|---|---|---|---|---|
| Started | 3 | 4 | 4 | 3 | 3 | 4 |
| Completed | 3 | 4 | 4 | 3 | 3 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Humalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20 | Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20 | Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20 | Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then Humalog | Humulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20 | Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog |
|---|---|---|---|---|---|---|
| Started | 3 | 4 | 4 | 3 | 3 | 4 |
| Completed | 3 | 4 | 4 | 3 | 3 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Postprandial glucose (PPG) values in participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal are reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug. Least square mean difference was calculated and tested using repeated measures analysis of variance with fixed effect for treatment.
| Milligrams per deciliter (mg/dL) | Humalog Alone | Humalog + rHuPH20 | Humulin-R + rHuPH20 |
|---|---|---|---|
| 60-minute PPG | 162.71 ± 32.28 | 144.67 ± 28.08 | 169.38 ± 28.64 |
| 90-minute PPG | 166.05 ± 34.53 | 143.62 ± 30.75 | 166.71 ± 33.83 |
| 120-minute PPG | 159.10 ± 30.73 | 138.24 ± 32.34 | 159.90 ± 39.56 |
| CBGMax(0-4hr) | 177.81 ± 33.46 | 165.38 ± 21.39 | 181.62 ± 31.61 |
Maximum serum insulin concentration (Cmax) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.
| Picomoles per liter (pm/L) | Humalog Alone | Humalog + rHuPH20 | Humulin-R + rHuPH20 |
|---|---|---|---|
| Maximum Serum Insulin Concentration (Cmax) | 3329.49 ± 1090.02 | 5661.92 ± 1307.75 | 3011.56 ± 962.31 |
Time to maximum serum insulin concentration (Tmax) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.
| Minutes (min) | Humalog Alone | Humalog + rHuPH20 | Humulin-R + rHuPH20 |
|---|---|---|---|
| Time To Maximum Serum Insulin Concentration (Tmax) | 74.29 ± 36.27 | 43.10 ± 16.01 | 81.67 ± 40.26 |
Time to early 50% maximum serum insulin concentration (early\[t50%\]) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, and 120 minutes after injection of each study drug.
| Minutes (min) | Humalog Alone | Humalog + rHuPH20 | Humulin-R + rHuPH20 |
|---|---|---|---|
| Time to Early 50% Maximum Serum Insulin Concentration (Early[t50%]) | 27.02 ± 8.67 | 18.71 ± 5.80 | 21.46 ± 8.19 |
Time to late 50% maximum serum insulin concentration (late\[t50%\]) for participants receiving Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.
| Minutes (min) | Humalog Alone | Humalog + rHuPH20 | Humulin-R + rHuPH20 |
|---|---|---|---|
| Time to Late 50% Maximum Serum Insulin Concentration (Late[t50%]) | 206.86 ± 41.66 | 123.93 ± 44.59 | 220.33 ± 51.98 |
Mean residence time from time 0 to the end of blood sampling (MRT\[last\]) for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.
| Minutes (min) | Humalog Alone | Humalog + rHuPH20 | Humulin-R + rHuPH20 |
|---|---|---|---|
| Mean Residence Time From Time 0 to the End of Blood Sampling (MRT[Last]) | 148.79 ± 22.46 | 108.23 ± 20.56 | 150.24 ± 27.32 |
Area under the concentration time-curve for serum insulin from time 0 to the end of blood sampling (AUC\[last\]) for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 during a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug. Least squares mean difference was calculated and tested using repeated measures analysis of variance with fixed effect for treatment.
| Minutes * picomoles /1000 (min*pm/1000) | Humalog Alone | Humalog + rHuPH20 | Humulin-R + rHuPH20 |
|---|---|---|---|
| Area Under the Concentration Time-Curve for Serum Insulin From Time 0 to the End of Blood Sampling (AUC[Last]) | 578.67 ± 144.66 | 668.33 ± 146.52 | 571.42 ± 132.04 |
Area under the time-concentration curve for blood glucose (AUC\[BG\]) for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), and Humulin-R + rHuPH20 following a liquid meal is reported. AUC(BG) values are reported for participants whose blood glucose (BG) was elevated higher than 160 milligrams per deciliter (mg/dL) or 140 mg/dL, or lower than 70 mg/dL within 4 hours of consuming a liquid meal. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug. Least squares mean difference was calculated and tested using repeated measures analysis of variance with fixed effect for treatment.
| Milligrams per deciliter * minutes | Humalog Alone | Humalog + rHuPH20 | Humulin-R + rHuPH20 |
|---|---|---|---|
| AUC(BG) >160 mg/dL | 2017.46 ± 2811.82 | 722.82 ± 1030.52 | 2509.65 ± 3332.36 |
| AUC(BG) >140 mg/dL | 4233.71 ± 4383.35 | 2696.54 ± 2548.03 | 4905.92 ± 4829.71 |
| AUC(BG) <70 mg/dL | 571.20 ± 850.07 | 197.00 ± 480.75 | 408.50 ± 602.29 |
Minimum postprandial glucose (PPG) in participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 following a liquid meal is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.
| Milligrams per deciliter (mg/dL) | Humalog Alone | Humalog + rHuPH20 | Humulin-R + rHuPH20 |
|---|---|---|---|
| Minimum Postprandial Glucose (PPG) | 76.38 ± 22.58 | 88.52 ± 27.37 | 75.62 ± 20.15 |
Percentage of participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 who did not experience hypoglycemia following a liquid meal is reported. Hypoglycemia was defined as any blood glucose values lower than 70 milligrams per deciliter (mg/dL) or symptoms of hypoglycemia responding to treatment with glucose. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.
| Percentage of participants | Humalog Alone | Humalog + rHuPH20 | Humulin-R + rHuPH20 |
|---|---|---|---|
| Percentage of Participants Without Hypoglycemia | 81.0 | 71.4 | 71.4 |
Time to percentage of exposure to insulin, as measured by area under the curve (AUC), following a liquid meal for participants who received Humalog alone, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 is reported. Blood samples were collected at 30, 20, 10, and within 5 minutes before and at 3, 6, 9, 12, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 420, and 480 minutes after injection of each study drug.
| Minutes (min) | Humalog Alone | Humalog + rHuPH20 | Humulin-R + rHuPH20 |
|---|---|---|---|
| Time to 10% Insulin Exposure | 46.05 ± 8.98 | 30.49 ± 7.13 | 43.41 ± 10.21 |
| Time to 50% Insulin Exposure | 135.73 ± 21.18 | 94.49 ± 20.06 | 137.52 ± 27.35 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Humalog Alone | — | 0/22 (0%) | 11/22 (50%) |
| Humalog + rHuPH20 | — | 1/22 (4.5%) | 5/22 (22.7%) |
| Humulin-R + rHuPH20 | — | 0/22 (0%) | 10/22 (45.5%) |
| Event | Humalog Alone | Humalog + rHuPH20 | Humulin-R + rHuPH20 |
|---|---|---|---|
| UrosepsisInfections and infestations | 0/22 | 1/22 | 0/22 |
| Pyelonephritis acuteInfections and infestations | 0/22 | 1/22 | 0/22 |
| DehydrationMetabolism and nutrition disorders | 0/22 | 1/22 | 0/22 |
| NephrolithiasisRenal and urinary disorders | 0/22 | 1/22 | 0/22 |
| Renal colicRenal and urinary disorders | 0/22 | 1/22 | 0/22 |
| Ureteric obstructionRenal and urinary disorders | 0/22 | 1/22 | 0/22 |
| Event | Humalog Alone | Humalog + rHuPH20 | Humulin-R + rHuPH20 |
|---|---|---|---|
| HeadacheNervous system disorders | 3/22 | 0/22 | 2/22 |
| NauseaGastrointestinal disorders | 2/22 | 1/22 | 1/22 |
| Upper respiratory tract infectionInfections and infestations | 0/22 | 0/22 | 2/22 |
| Limb injuryInjury, poisoning and procedural complications | 0/22 | 1/22 | 0/22 |
| Skin lacerationInjury, poisoning and procedural complications | 0/22 | 1/22 | 0/22 |
| Injection site painGeneral disorders | 0/22 | 1/22 | 1/22 |
| DiarrhoeaGastrointestinal disorders | 1/22 | 1/22 | 0/22 |
| Abdominal painGastrointestinal disorders | 1/22 | 1/22 | 0/22 |
| Abdominal pain upperGastrointestinal disorders | 0/22 | 0/22 | 1/22 |
| InfluenzaInfections and infestations | 1/22 | 0/22 | 0/22 |
Participants who received at least 1 dose of Humalog, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 during dose-finding (DV) visits or experimental (data gathering) visits.
| Age, Continuous(Years (yr)) | Overall Study |
|---|---|
| Mean | 52.2 ± 8.07 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 9 |
| Male | 14 |
| Ethnicity (NIH/OMB)(Participants) | Overall Study |
|---|---|
| Hispanic or Latino | 9 |
| Not Hispanic or Latino | 14 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall Study |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 4 |
| White | 17 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Overall Study |
|---|---|
| United States | 23 |
The record gives a start of Jul 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Lispro · Insulin, Regular, Human · Hyaluronidase (human recombinant)